about
sameAs
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityFusarium: Molecular Diversity and Intrinsic Drug ResistanceCandida albicans AGE3, the ortholog of the S. cerevisiae ARF-GAP-encoding gene GCS1, is required for hyphal growth and drug resistanceGenome Anatomy of Pyrenochaeta unguis-hominis UM 256, a Multidrug Resistant Strain Isolated from Skin ScrapingResistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypesTranscriptional profiles of the human pathogenic fungus Paracoccidioides brasiliensis in mycelium and yeast cells.Pharmacological advances in the treatment of invasive candidiasis.Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization.Beneficial effect of Mentha suaveolens essential oil in the treatment of vaginal candidiasis assessed by real-time monitoring of infection.Peptide-based Antifungal Therapies against Emerging Infections.Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis.Metabolism and resistance of Fusarium spp. to the manzamine alkaloids via a putative retro pictet-spengler reaction and utility of the rational design of antimalarial and antifungal agents.Biochemical characterization of an anti-Candida factor produced by Enterococcus faecalisCabanillasin, a new antifungal metabolite, produced by entomopathogenic Xenorhabdus cabanillasii JM26.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingImpact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profilingUpdate on the laboratory diagnosis of invasive fungal infectionsFK520 interacts with the discrete intrahelical amino acids of multidrug transporter Cdr1 protein and acts as antagonist to selectively chemosensitize azole-resistant clinical isolates of Candida albicans.Identification of clinically relevant fungi and prototheca species by rRNA gene sequencing and multilocus PCR coupled with electrospray ionization mass spectrometry.Virulence Factors and Anti Fungal Sensitivity Pattern of Candida Sp. Isolated from HIV and TB Patients.Validation of High Resolution Melting Analysis (HRM) of the Amplified ITS2 Region for the Detection and Identification of Yeasts from Clinical Samples: Comparison with Culture and MALDI-TOF Based IdentificationClinical significance of the isolation of Candida species from hospitalized patients.Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.Mutation of G234 amino acid residue in candida albicans drug-resistance-related protein Rta2p is associated with fluconazole resistance and dihydrosphingosine transportVoriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.Human lactoferrin induces apoptosis-like cell death in Candida albicans: critical role of K+-channel-mediated K+ effluxGain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.Synthesis, characterization, and antimicrobial evaluation of carbostyril derivatives of 1H-pyrazole.Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance developmentNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy--status quo.Candida urinary tract infection and Candida species susceptibilities to antifungal agents.Dynamics of Mixed- Candida Species Biofilms in Response to Antifungals.HIV/AIDS-Associated Cryptococcosis in Portugal Spanning the Pre- to Post-HAART Era: A Retrospective Assessment at the Genotypic Level Based on URA5-RFLP.Antifungal activity against Cryptococcus neoformans strains and genotoxicity assessment in human leukocyte cells of Euphorbia tirucalli L.Antifungal resistance and new strategies to control fungal infections.Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans.
P2860
Q24530412-FEAA4576-7DFE-4B84-8791-36CC44624441Q26750950-7897145D-0CED-45EF-9897-C10025B4AF8BQ28475025-5D843B3E-4962-4BEF-BBD7-1F594F2FCAFAQ28554076-131E1E54-2345-4764-A190-7140E71E124AQ28731332-FC78AA96-E645-453C-99FE-FB8A24315187Q31162652-08091938-D2DB-4B44-B288-0B93D8539DB4Q33232599-2650279D-5AA1-46DB-8FA5-2EDCFE249DF5Q33715355-351A51A8-FBA6-4DC1-8B7F-683E663E47A7Q33830972-142CE9B2-0F85-4012-8DFE-583BB05365D9Q33862289-0BC5B2AD-F86C-4B84-B76E-A8F06A4ADBDBQ33993054-77EB8281-DF5C-414A-99C7-105E55E0E180Q34069955-5EE53E24-EDC4-46E5-9B63-BEF15B105B6DQ34325020-310D695E-4098-4C85-92D6-C66C99193893Q34350159-AA8B5822-E408-47B0-8EC7-C3862D566AEFQ34647337-35474B86-992C-45A9-B745-3676F11D999EQ34721695-BF31E5AB-35E7-4AD2-B221-BC73BD1785ACQ34721706-77B3E867-D98F-4594-A84A-8835D417E84CQ35010667-A348EB71-1144-4082-9B9F-5A34FB6BAB68Q35120697-5E20013B-8E99-4377-B9A5-112E8EBB57A2Q35169912-3613EF45-CC1A-4422-9BFA-59C026FC2BCBQ35533049-5CB46440-9F1F-4310-8B4C-68FE427345D0Q35752374-B373340B-F159-4B3F-A6F7-61F60A2D2C38Q35881281-A0E71032-6126-42E1-B7EA-7BA6D94FDC39Q36482736-750CAA38-39AA-4AA6-A570-6D082D6DA581Q36483019-3BD3133D-5FBA-40CD-BA19-39C988CDC527Q36696390-AED858CB-0839-4E27-BF45-DBA0CF7EBFF1Q36949508-05591F62-F985-47A0-9D9B-C59E0A0FCFB8Q36993519-E5258B49-7ABB-476A-8873-E28C11148706Q37099309-FB9F6306-6BCF-4576-BA6E-740299244890Q37214044-041387CC-D0DA-4DDF-B47E-E8D87328BC4FQ37381931-601F244F-1143-409C-BC61-D6AB4F8295E4Q37608276-09AC5CD7-3383-48E4-91CD-F21300E21DE8Q37889382-E57EA1F8-C28E-49C1-88C6-6D7FFD93EFFEQ37961230-76C1403B-D82C-46C6-9A4F-41A771C3358CQ38117065-85A3D96D-1A30-42B1-966C-1435147E7B19Q38603971-30D7CDBE-A81E-4028-8936-49C18E4AA5E4Q39202141-138BE3EB-54AF-4DFB-9342-6E06F4FEBD8EQ39287238-993EA108-C65F-4968-B071-75A4C7F9FEEFQ39751373-15ADCA75-DB96-40F6-92DC-F9516C7B18FFQ40443248-7A3761BD-4715-4AF2-9D9B-AA5676C0AE2B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antifungal resistance in pathogenic fungi
@ast
Antifungal resistance in pathogenic fungi
@en
Antifungal resistance in pathogenic fungi
@nl
type
label
Antifungal resistance in pathogenic fungi
@ast
Antifungal resistance in pathogenic fungi
@en
Antifungal resistance in pathogenic fungi
@nl
prefLabel
Antifungal resistance in pathogenic fungi
@ast
Antifungal resistance in pathogenic fungi
@en
Antifungal resistance in pathogenic fungi
@nl
P2860
P3181
P356
P1476
Antifungal resistance in pathogenic fungi
@en
P2093
Sofia Perea
Thomas F Patterson
P2860
P304
P3181
P356
10.1086/344058
P407
P577
2002-11-01T00:00:00Z